VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15Surgery improves survival of women over age 80 with breast cancer (28/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=76&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0076\2015_0076_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Research Unit in Biomedicine and Translational Research in Gynecology and the Gynecological Service of the Vall d’Hebron University Hospital, led by Dr. Antonio Gil, have demonstrated that surgery is the best option to treat women over 80 years with breast cancer in early stages (I and II). The conclusion, published in the European Journal of Surgical Oncology, was obtained after comparing the evolution of 465 women with breast cancer treated in Vall d’Hebron between 1995 and 2012.&nbsp;&nbsp; Nearly the 30% of women diagnosed with breast cancer are over 80 years old and have, in most of the cases, hormonal tumors. In this situation, oncologists have two options: to operate them in order to remove the tumor, to add radiotherapy or chemotherapy and to give hormone treatment (if it’s necessary); or to administrate a primary endocrine treatment without surgery. One of the principal authors of the study, who is an associate doctor of the Gynecology Service and the Centre of Breast Cancer in Vall d’Hebron, Dr. Tomás Cortadellas, said: “physicians sometimes choose hormone therapy, the less aggressive option, just to avoid the side effects of the surgery standard treatment". Hormone therapy blocks the hormones and stops the tumor growth, but only for a few years. Specifically, researchers have shown that patients treated with hormone therapy in Vall d’Hebron presented an average of 50 months survival, while the operated women lived 109 months after the diagnosis. Besides the survival analysis in both groups, researchers observed that, in the operated group, some of them received a less aggressive surgery with suboptimal oncology results. This clinical decision neither help the patients: the ones who received an optimal surgery treatment (removal of the tumor, the sentinel node and other nodes, if it’s necessary) lived, on average, two years and a half more than the ones who received a minor surgery. At the time of doing the comparative analysis of both groups, Dr. Cortadellas studied patient’s comorbidity (that is to say, the diseases or health problems that patients also presented) to determine if their state of health could influence the treatment they received. To do this, he calculated the Charlson comorbidity index, which evaluates the patient’s life expectancy in the next 10 years. The results were homogeneous: “all the patients included in the study presented the same comorbidity, so we can compare both treatments”, said the physician. A part from this index, in order to confirm the homogeneity of the groups, he also compared other parameters like the chemotherapy and radiotherapy dose they received, the lymphovascular invasion, the tumor stage or the expression of the gene HER2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The increase in longevity requires changing the treatment <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-se</td></tr></table>comunica@vhir.org (VHIR)Tue, 28 Apr 2015 00:00:00 GMTVHIR showed at the BCN Science Festival the proteins hidden in the fruits (27/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=75&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0075\2015_0075_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> How many proteins are hidden in the fruits? This is the question that Miguel Aranda, researcher from the Kidney Physiopathology group at VHIR, asked to the visitors of the NOVUM Barcelona Science Festival. On Sunday morning, many children participated with their families in his workshop, located at the Plaça de les Glòries, in Barcelona, in order to know the role of the proteins in fruits and humans. The aim of Miguel’s workshop was to explain the role of proteins and why is useful to count them. In his lab, researchers study pathologies such as Dent’s disease that is characterized by the loss of proteins through the urine and leads to chronic kidney failure. The Barcelona Science Festival, which in the past editions was located at the Parc de la Ciutadella, was organized by the Barcelona city council with the aim to promote the activity carried out by research centers and scientific associations from the city. Read the poster of the workshop on this link. </td></tr></table>comunica@vhir.org (VHIR)Mon, 27 Apr 2015 00:00:00 GMTRegistrations open for the 2nd edition of the Master's Degree in Translational Biomedical Research (27/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=27&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0027\2015_0027_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR), associated to the Universitat Autònoma de Barcelona, opens the registrations of the 2nd edition of the Master’s Degree in Translational Biomedical Research UAB-VHIR, which will start on October 2015. Registrations will be open until September 2015, but the first students will be admitted on April. As a new feature of this year’s edition, students will have to choose three out of the six optional subjects, taught by researchers and clinicians currently working at Vall d’Hebron University Hospital. The optional subjects are: Brain and Nervous Peripheral System Diseases; Cardiovascular and Kidney Diseases; Oncology Diseases; Liver and Digestive Diseases; Microbiology, Infectious Diseases and Critical Pathology; and Respiratory, Immune, Systemic and Endocrine System Diseases. The program will also offer new lessons on transversal competences, such as communication and outreach, business development, national and international calls, and project management. The aim of the master is to generate excellent young researchers by providing them with the necessary combination of scientific and medical knowledge and skills to contribute successfully to the future of translational medical research. It is addressed to research career, providing access to a PhD program related to the biomedicine area that the students had previously chosen for their training program and internship. In this regard, the master is an excellent occasion for working in a biomedical research laboratory with first-rate scientists and clinicians. Finally, for the second consecutive year, students will have the chance to apply for a grant that will cover all the tuition and course costs. Last year 6 students were granted, but for this second edition the number of students granted has yet to be decided. Registration process </td></tr></table>comunica@vhir.org (VHIR)Mon, 27 Apr 2015 00:00:00 GMTVHIR wins Best in Class 2014 to the best research and innovation center (24/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=226&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0226\2014_0226_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d'Hebron Institute of Research (VHIR) has received this morning the Best in Class award to the best research and innovation center, one of the prizes organized by the journal Gaceta Médica and the Cátedra de Innovación y Gestión Sanitaria de la Universidad Rey Juan Carlos. The Unit of transplantations of haemopoietic progenitors at Vall d'Hebron University Hospital (HUVH) and the Multiple Sclerosis Center (Cemcat) also have been awarded in a ceremony in which were represented the best hospitals of Spain. This award fits perfectly with the aim of VHIR, which mission describes it as an institution that promotes and developes not only research but also biomedical innovation. VHIR does research to improve people's lives, and its researchers work to transfer to the society the knowledge they got investigating in the&nbsp; labs. Their results don't stay in the labs, but seek to be applied in patients in mid term. Dr. Joan Comella, VHIR's director, received the award in a cerimony that took place in the World Trade Center of Barcelona with the presence of the Catalan Health Minister, Dr. Boi Ruiz. </td></tr></table>comunica@vhir.org (VHIR)Fri, 24 Apr 2015 00:00:00 GMTVHIR proposals for Sant Jordi (23/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=71&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0071\2015_0071_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Here you have our three recommendations for this Sant Jordi’s Day: ‘En Roc al Planeta Mascareta’, ‘Nano-Oncology, the Turning Point’ and ‘Aians’. These three books are written by professionals from Vall d’Hebron Hospital. En Roc al Planeta Mascareta Roc is a kid who after escaping from the paws of a terrible dragoon (the disease), with the help of his horse (his family), arrives to Mascareta Planet (the hospital), where he will live many adventures and many people will help him (clinicians, nurses, psicologists…). The adventures represent different phases of the disease. The authors of the book are two nurses of the Oncohematology Service, Raquel Moya and Carmen Biota, and the Acuna Patata association. The price of the tickets is 6 euros that will directly go to the research in Child Cancer at VHIR. You can buy the book on Sant Jordi’s Day from 9AM to 3.30PM in front of the maternal and child building. You can also buy it through the website of the association and by email to Dr. Miguel Segura. Nano-Oncology, the Turning Point “Far from the public perception that nanotechnology and nanomedicine are still trending topics of science fiction, a new emerging reality is deepening its roots in our society and people begins to realize that a new giant wave is going to smash our shores in the form of a technological revolution... and the impact might even go beyond imagination”, wrote Dr. Simó Schwartz, head of the CIBBIM-Nanomedicine, in the foreword of Prof. Victor Puntes’ book.&nbsp; Sharing his professional and personal experiences in the laboratory and the teaching, Dr. Puntes, who is currently working as a researcher in the CIBBIM-Nanomedicine area at VHIR, leads us in this fascinating revolution through the pages of his book. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Apr 2015 00:00:00 GMTRecognition of the professional career of three researchers from VHIR (23/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=74&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0074\2015_0074_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr Josep Sánchez de Toledo, responsible of the group of Translational Research in Child Cancer in the Vall d’Hebron Research Institute (VHIR) and responsible of the Oncology and Child Haematology Service was awarded with the Medalla Josep Trueta. This recognition is given by the Generalitat de Catalunya with the objective of honoring professionals or entities that have stood out for the services rendered in view of progress and improving health. Dr Sánchez de Toledo combines his clinical work in children with tumors and bone marrow transplants with the most advanced research in childhood cancer. To recognize his intensive activity for the children welfare and his leading research, his research group collects donations from important entities, patients associations and citizen’s initiatives, and obtains European and Catalan competitive aids, like La Marató de TV3. New memberships of the Real Academia Médica Besides, two other researchers received also an important recognition for their work in health care and research. The Reial Acadèmia de Medicina de Catalunya designated corresponding academician the Dr. Ricard Pujol, responsible of the Immunology research group in VHIR, and Dr Santiago Ramón y Cajal, responsible of the Oncology and Pathology Molecular research group. Dr Pujol, nowadays, is combining his work in VHIR with being the responsible of the Immunology Service of the Hospital and is a research adviser of the Institut Català de la Salut (ICS). In the field of the research, professor Pujol is an international leader in the study of the autoimmune diseases, especially in the Graves disease, and either in the identification of new biomarkers to diagnose these illnesses. Dr Ramón y Cajal also shares his dedication in VHIR with being the responsible of the pathological Anatomy Service in the Hospital. In the research field, he is a pioneer in the study of the signaling pathways in human tumors, the study of the aging gene expression in tumors and the identification of therapeutic targets associated with the tumor progress and the pharmacological resistance in colorectal carcinomas. A part from this recognition, Dr Ramón y Cajal has been recently chosen member of the Real Academia Nacional de Medicina. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Apr 2015 00:00:00 GMTCome to the Party of the Research at Vall d'Hebron (21/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=69&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0069\2015_0069_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Get it in your diary: Saturday 23rd of May, Pavelló Olímpics (in front of the University Hospital Vall d’Hebron). We have organized a lot of activities and surprises to celebrate with all the society our 20th birthday, and also as a preamble of the 60th birthday of our Hospital. This day you will see what kind of research we do in VHIR, through scientific workshops and an exhibition of amazing photographs (the winning images of the science photography competition). But especially it will be a feast day, with activities for all the family: bouncy castles, music, games for the children, dancing, magic, sports and a lot of solidarity. There will be sweepstakes, a big solidarity paella, merchandising and deep gratitude, because with these activities we want to make the society aware of the importance of the research and bring the opportunity to collaborate with the biomedical research in VHIR. The party will be amused by the Magician Andreu, the TV star Enric Company and the VHIR, our mascot! In the afternoon there will be the winning group of the last edition of the TV program Oh Happy Day!, that will perform on the Pavilion’s stage. But there will be more music: los Fugados de Alcatraz, who have composed a song for us called ‘Aire’ that will be sung by them and the Choir of the Vall d’Hebron, Manu Guix, Boxet, la Gira-sol and other special invitees. So, don’t think it twice. We want to see you on Saturday 23rd of May from 10h to 20h in the Pavelló Olímpics. You will have a nice day with surprises and discoveries! </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Apr 2015 00:00:00 GMTVall d'Hebron releases 250 balloons, one for each known primary immunodeficiency disease (20/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=66&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0066\2015_0066_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Research Institute (VHIR) is joining, one more year, the celebration of the World Primary Immunodeficiency Week, which has the objective of increase the recognition and the diagnosis of these diseases. This year 250 ballons have been released with the collaboration of the 5th course students of the School Jesuïtes de Sant Gervasi-Infant Jesús and with the support of Designa SCP. Children diagnosed with Primary Immunodeficiency Diseases (PID) in the Hospital have also participated, with their families and clinicians. Primary Immunodediciency Diseases (PID) PID is a group that includes more than 250 different rare or minority illness caused by alterations in the immunology system of the children. They affect one in every 2.000 live newborns, and these people are susceptible to suffer severity infections that, in case of not being treated properly, could be dangerous or cause lasting damage. The early diagnosis and the research to find more effective treatments are very important to assure the patients survival and to improve their quality of live, reducing the lasting damage. Nowadays PID isn’t a sanitary priority and neither social. PID in the Vall d’Hebron Hospital The University Hospital Vall d’Hebron leads the health attention of the pediatric patients in our country, with more than 700 diagnosed patients, the 70% of the total in Catalonia, according to the figures reported by the PID European Register of the European Society for Immunodeficiency and by the Jeffrey Modell Foundation (JMF). And among them, more than 400 are under 18 years old. In VHIR, the research groups of Infection in immunocompromised pediatric patients and Immunology investigate about it. <span style=" font</td></tr></table>comunica@vhir.org (VHIR)Mon, 20 Apr 2015 00:00:00 GMTVHIR has obtained the HR Excellence in Research recognition (20/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=68&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0068\2015_0068_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Research Institute (VHIR) has obtained the recognition of the European Commission HR Excellence in Research. This recognition proves that VHIR endorses the general principles of the European Charter for Researchers and a Code of Conduct for the Recruitment of Researchers (Charter &amp; Code), and firmly supports its commitment in improving internal policies and procedures. This recognition of excellence is an opportunity to establish a comprehensive and coherent Human Resources Strategy, that should allow to achieve international visibility. On March 2014, the VHIR initiated the process for the award recognition by performing a first analysis of the relevant applicable legislation and the alignment of the Institution with the Charter and Code principles. Then, specific Focus Groups were organized in order to involve all personnel and to establish priority actions: Focus Group of administration and structural personnel, Focus Group of predoctoral and postdoctoral researchers and laboratory technicians, Focus Group Tenure Track researchers and Focus Group of researchers. Thanks to the collaboration of these collectives in the Focus Groups, the project has been a very positive and enriching experience. You can find in our website the Action Plan of the accreditation for the next 4 years, and the information about the European Charter for Researchers and a Code of Conduct for the Recruitment of Researchers and the Human Resources Strategy for Researchers. </td></tr></table>comunica@vhir.org (VHIR)Mon, 20 Apr 2015 00:00:00 GMTPossible new strategies to combat epithelial metastatic cancer have been described (16/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=63&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0063\2015_0063_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> An article published by researchers from the School of Pharmacy of the University of Lisbon and from the Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine) from the Vall d'Hebron Research Institute (VHIR) includes the latest discoveries in the field of epithelial metastatic cancer and considers the possibility of opening new therapeutic fronts for the treatment of the breast cancer. The article, published in the specialized magazine Current Gene Therapy, focus on the process by which epithelial cells in the body become stem cells, process known as Epithelial Mesenchymal Transition (EMT), and what gene regulation strategy could be used to control this process in tumors, reducing the dangerousness of the breast metastatic cancer. EMT is useful to conceive organs, to regenerate tissues or for the wound healing, but it also plays a very important role in metastatic cancers with an epithelial origin. In this phenomenon, epithelial cancer cells lose their morphological features, acquiring the features of an undifferentiated cell, and get the propriety to survive without being attached to other cells. In consequence, undifferentiated cells are able to detach from the epithelial tissue and travel through the blood to colonize other tissues where they establish and develop the metastasis. Many intracellular changes are necessary for this process, and they are, then, clue elements in the regulation of the tumor’s invasive and metastatic capacity. Some of these regulatory factors are presented in this article as possible therapeutic target, taking into account they have different roles in each kind of tumor and in each tumor’s evolution stage.&nbsp; According to researchers, new methods of gene therapy could allow the modification of these regulatory factors’ expression, keeping the cancer in its early stages, before they become undifferentiated, when the cancer is more sensible to the chemotherapy. This would allow control cancer’s invasive potential and raise the efficacy of the treatment because, often, cells that suffer this phenomenon don’t respond to the pharmacological therapy.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Apr 2015 00:00:00 GMTThe Association for the Familial Hypomagnesemia gives 15,000€ for the research in VHIR (16/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=65&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0065\2015_0065_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Association for the Information and the Research in Familial Hypomagnesemia (HIPOFAM) has given 15,000 euros to the Kidney Physiopatology research group of the Vall d’Hebron Research Institute (VHIR) to investigate this rare disease. With this contribution, the group leaded by Dr Anna Meseguer will hire a junior researcher who will be fully dedicated to the research in Familial Hypomagnesemia, as part of a project coordinated by Dr Gema Ariceta, responsible of the Paediatric Nephrology Service at the Vall d'Hebron University Hospital. The project, funded by the Fondo de Investigación Sanitaria, has the objective of ultrasequencing the RNAm and the microRNAs obtained from exosomes of patients with familial hypomagnesemia, hypercalciuria and nephrocalcinosis with known mutations in the claudina 19 gene. The familial hypomagnesemia affects the kidney because, due to a protein malfunction, the organ doesn’t reabsorb the magnesium. That produces the magnesium is expelled through urine and its blood level is very low. If you want, you can also contribute. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Apr 2015 00:00:00 GMTVHIR leads an international course in sepsis and pneumonia (15/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=64&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0064\2015_0064_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Once again Vall d’Hebron brought together national and international experts in the field of sepsis and pneumonia at the International Course on Antimicrobial Strategies in Infection and Sepsis (ICASIS), hosted in Sitges on April 13th and 14th. In this year’s edition participated professionals from Germany, France, Italy, Belgium, Turkey, Portugal, Switzerland and Spain. Clinicians and researchers discussed the latest advances in innovation and management of patients with serious infections, both from bacterial and fungal origin. In a session coorganized by CIBERBNN and CIBERES , participants talked about the new molecular diagnostics techniques applied to sepsis, including PCR techniques, mass spectrometry and nanotechnology. They also presented clinical cases with innovative treatments by multiresistant bacteria, septic shock complications, and the most recent findings related to biomarkers. The course was chaired by Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia and Sepsis group at Vall d’Hebron Institute of Research (VHIR), and coordinated by Dr. Cristopher Mazo, researcher from the same group. The next edition will be the 30th and 31st of March of 2016 and will be devoted to sepsis in immunocompromised patients. </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Apr 2015 00:00:00 GMTRoche's world leaders visit VHIR (14/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=62&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0062\2015_0062_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Every year Roche organizes a world meeting with all its officers. Two days where the pharmaceutical giant meets to visit one of their offices and reflect on their present and future. In 2015 has arrived the moment to visit Roche Sant Cugat, in Barcelona. In this context we must understand the visit of its top leaders to Vall d'Hebron University Hospital and VHIR. During two hours, within a tight schedule of two days, Roche has decided that one of the activities of its annual meeting would be visiting our hospital and research institute. The reason is easy, Vall d'Hebron is one of the leaders of the pharmaceutical in innovative projects in our country, so that's the reason why the responsible for Roche Spain wanted to show their international colleagues the potential of the collaboration with our campus. The meeting has been chaired by the manager of HUVH, Dr. Vicente Martínez Ibáñez, and the head of research and innovation of the Catalan Ministry of Health, Gabriel Capellá. Also, Ramon Maspons, responsible of Innovation of the Health Quality and Evaluation Agency of Catalunya (AQuAS) made a presentation to inform the responsible of Roche about the data indicating the good work being done in our country related to research and innovation. On the part of Roche have been present the senior management of the Leadership Team, Roland Diggelmann, Division COO, Dan Zabrowski, Global Head Tissue Diagnostics and Jean-Claude Gottraux, Global Head Professional Diagnostics, and other regional leaders to complete twenty representatives. As to VHIR, besides its director, Dr. Joan Comella, who presented the hospital and its research, there were researchers from the liver diseases group. Represented by Dr. Josep Quer, presented a unique breakthrough that will serve to develope a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations. On behalf of VHIO, besides the presence of its director, Dr. Josep Tabernero, has intervened Dr. Joaquin Arribas, who presented the possible developments of diagnostic applications based on platforms of new generations of Roche, the basis of RIS3CAT project, in which are jointly working VHIR, VHIO and Roche. "It is a pleasure to visit Barcelona and being able to see first hand the full potential of the relationship between Roche and Vall d'Hebron. We were impressed to see what it's being done and what we can do together in the future," said Roland Diggelmann to close the meeting. </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Apr 2015 00:00:00 GMTThe Bangle, solidarity bracelet with childhood cancer (13/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=61&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0061\2015_0061_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Season's Barcelona, an online jewelry company of Sant Cugat, has launched the solidarity collection Bangle, which consists of several unisex bracelets. 100% of the profits will be for the group of translational research in childhood and adolescence cancer at Vall d'Hebron Institute of Research (VHIR). The initiative has the support of the radio Djs of Los 40 Principales show, Xavier Martinez and Ingrid Sunyer, also from Sant Cugat, who are committed to encouraging young people to contribute to this charity project. The presentation of the collection, which took place at the House of Culture of the Town Hall of Sant Cugat, was chaired by the Deputy Mayor of Citizen Services, Susanna Pellicer, who stressed that "the town hall will promote that many people can buy it and raise funds for research." The head of the research group and of Oncology and Hematology Pediatric Service at Vall d'Hebron University Hospital, Josep Sánchez de Toledo, thanked Season's Barcelona for its commitment. "We are very pleased with this initiative. The money raised will fund one of the three research lines of our laboratory," he said. Meanwhile, the two designers and owners of Season s Barcelona, Charo Álvarez and Ester Guàrdia, explained that "from the moment we founded the company wanted to be involved in helping children and being a responsible company". These jewels, made of gold or leather, cost 20 euros. The purchase can be made through the website of the company. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Apr 2015 00:00:00 GMTDr. Bruno Garcia arrives to Barcelona after 99 days around the world in a boat (10/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=60&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0060\2015_0060_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Bruno is at home. He will have time to rest before rejoining his activity as cardiologist at Vall d'Hebron University Hospital, but yesterday, along with his brother Willy, stepped on dry land after more than 99 days on his boat, We Are Water, with which on Thursday April 9, more than 14 days after the arrival of the winner, finished fifth in the Barcelona World Race. Brothers Bruno and Willy Garcia, an example as sailors and persons were exhausted but elated, happy and satisfied a few minutes after their arrival to the Portal de la Pau, where a crowd were waiting form them on a sunny afternoon in Barcelona. "Going with my little brother has been the biggest success I could ever have. Surely there are better navigators, but I don't have a brother like him, it has been tremendous, tremendous!", assured Bruno with tears in his eyes. More than three months ago we remember the image of the presentation of the boat, the last to be prepared, but good enough to compete with the best. One day late in December, when Bruno posed with the logo of VHIR, which has showed throughout the race with pride for over 23,000 miles in which have suffered many changes in conditions. "You can't imagine how hard it is to endure these conditions with this boat, both the sea and the boat are very demanding, and we have been very fast, but those who have won us have gone even faster, because they are professionals. And I love my profession as much as sailing", says Bruno. For almost one hundred days have brought the solidarity message from We Are Water and Vall d'Hebron Institute of Research on their boat. The experience has made them appreciate the importance of these messages. "I can only say that the world is not as great as we all thought. Because if two brothers as we have been able to get around with a sailboat, which by the way is a wonder, then it's smaller than we think. And therefore, we have to care." Caring for the world and the people who inhabit it. And a message to overcome the daily difficulties. "You miss the fresh food ... a tomato would taste like the glory to me now! But then there aren't so many things that you need, the great lesson is that you can manage yourself without many things." </td></tr></table>comunica@vhir.org (VHIR)Fri, 10 Apr 2015 00:00:00 GMTVHIR talks about research on child cancer at the Live Research Fair (08/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=59&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0059\2015_0059_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Which are the differences of cancer during childhood and adulthood? Why does it take so long for the approval of new drugs? Are there any clinical trials for child cancer? These are some of the questions that the members of the Translational Research in Child and Adolescent Cancer group at VHIR have answered to the students that have visited the Ágora room at the CosmoCaixa. The museum hosts from the 8th to the 11th of April the 13th edition of the Live Research Fair, in which participate 12 Catalan research groups. At Vall d’Hebron’s stand, researchers have 3 posters in which answer some of these questions and describe the experiment that have moved from the laboratory to the fair: a cell proliferation and viability essay. In this experiment, students will test the effect of some drugs, using a simple and quick method, and check its efficacy through the microscope granted by Izasa Scientific. The fair is organized by the Parc Científic de Barcelona, with the support of Obra Social “la Caixa” and the Barcelona city council. The aim of the event is to bring science to society and promote scientific vocations among young people. Posters </td></tr></table>comunica@vhir.org (VHIR)Wed, 8 Apr 2015 00:00:00 GMTVHIR hosts a strategic workshop to implement personalized medicine in Europe (07/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=58&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0058\2015_0058_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Members of the PerMed European Project, called “Personalized Medicine 2020 and beyond – Preparing Europe for leading the global way”, joined at Vall d’Hebron Institute of Research (VHIR) to agree and finish the strategic research and innovation agenda to bring forward the implementation of personalized medicine for the benefit of society.&nbsp; VHIR is represented by the Instituto de Salud Carlos&nbsp; III, who leads the agenda’s work package. Personalized medicine has become an international priority and one of the most important issues of Horizon 2020, the programme of the European Comission. 27 international entities in the field of biomedical research participate in PerMed with the aim to develop the strategic agenda, implement the personalized medicine and complement existing activities by identifying and promoting promising research topics. The publication of the strategic research and innovation agenda is expected before summer. The agenda will suggest common activities and potential joint funding in relevant areas of personalized medicine research. The proposed implementation plan will point out priorities and recommend instruments and timelines for future European research policies. </td></tr></table>comunica@vhir.org (VHIR)Tue, 7 Apr 2015 00:00:00 GMTFour biomedical research centres in Barcelona join forces to bridge the gap between investigation and clinical practice (31/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=56&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0056\2015_0056_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Centre for Genomic Regulation (CRG), the Institute for Research in Biomedicine (IRB Barcelona), the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), and the Vall d’Hebron Research Institute (VHIR)—the two last institutes linked to the Clínic Hospital and Vall d’Hebron Hospital, both university training hospitals in Barcelona—have designed a training programme called “PhD for Medical Doctors – PhD4MD”. This is a pioneering initiative seeking to speed up the transfer of results generated by biomedical research activities in Spain to clinical practice—a process commonly known as translational medicine. The commitment to biomedical research in Spain over the last ten years has yielded its rewards and now several Catalan research centres are placed among the leading and most prestigious centres in Europe and worldwide. A solid framework for basic biomedical research has been slowly put together and the time is now ripe to join forces with the strong translational research undertaken in hospital in order to transfer the knowledge generate into clinical practice. In this regard, collaboration between basic research centres and hospitals is essential, as is the focus on multidisciplinary projects that include medical doctors who have received specialized training for the purpose. This is precisely what “PhD for Medical Doctors – PhD4MD” is about—a collaborative programme promoted by the Catalan centres CRG, IRB Barcelona, IDIBAPS and VHIR, in which physicians in Spain that have already completed&nbsp; their Specialised Health Training (known as MIR in Spanish) perform&nbsp; cutting-edge PhD research projects. “It is a challenge for research centres to translate their findings into clinical practice. It is crucial to further basic knowledge, but all this effort makes no sense if there is no benefit for public health”, explains Luis Serrano, director of CRG. “We need to have medical doctors who are willing to collaborate with us and to train in order to ensure that our research reaches the hospital setting”, concludes Serrano. The first call, which will serve as a pilot programme, will offer four fellowships for medical doctors that wish to be trained in research and to do a PhD over three years. Joan Comella, director of VHIR comments that, “the experience of hospitals in clinical and translational research will help basic research centres to bring their knowledge to the bedside”. In his experience, “together, medical doctors and researchers form a perfect team to improve public health”. The four participating centres will work on collaborative projects that involve a basic research group (at IRB Barcelona or CRG) and a translational or clinical research team (at VHIR or IDIBAPS). “The four centres have opened an internal call to select outstanding projects orientated to translational medicine and with objectives that can be achieved in a period</td></tr></table>comunica@vhir.org (VHIR)Tue, 31 Mar 2015 00:00:00 GMTEnvía un SMS con la palabra DIDAC al 28014 (30/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=54&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0054\2015_0054_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Desde hoy ya se puede contribuir a la investigación de las inmunodeficiencias primarias (IDPs) en el Vall d’Hebron Institut de Recerca (VHIR), enviando un mensaje con la palabra DIDAC al 28014*. El importe íntegro del SMS, 1,20€, irá destinado a la investigación de este conjunto de enfermedades raras que afectan a niños como Didac. Didac tiene 4 años y una enfermedad rara que afecta a su sistema inmunológico. Sus padres, Julia e Iván, llevan un año y medio haciendo grandes esfuerzos por recaudar fondos para que el equipo de investigadores del Vall d’Hebron pueda seguir con la investigación en inmunodeficiencias primarias, una patología que se llevó por delante la vida de Juan, el hermano de Didac, con tan solo tres años. Gracias a los donativos de muchas personas anónimas, la investigación en IDPs ha conseguido hallar la mutación que causa a Didac este defecto genético y ahora Didac podrá someterse a un trasplante de médula ósea. Con el objetivo de poder ayudar a más niños como Didac, sus padres han lanzado esta campaña de SMS Solidarios para recaudar fondos para la investigación en IDPs y sensibilizar a la sociedad sobre la gravedad de estas enfermedades del sistema inmunitario que predisponen al paciente a sufrir más infecciones de las normales y de forma más grave, llegando a producir linfomas, leucemias e incluso, la muerte. Como explica el padre de Didac, “estas enfermedades no son raras porque sean difíciles de curar, sino porque no se ha dedicado la suficiente investigación”. En concreto, los fondos que se recauden a través de esta campaña y de los donativos que se reciban para esta causa en Yo Investigo, se invertirán en la recogida y preservación de muestras de sangre extraídas en el hospital, a través del Biobanco HUVH. Con estas muestras, los investigadores podrán dar consejo genético a futuros padres, y avanzar en el estudio de los defectos genéticos que están detrás de estas enfermedades. En el Vall d’Hebron estudian las IDPs el grupo de investigación de Infección en el Paciente Pediátrico Immunodeprimido (del que forma parte el Dr. Pere Soler que está tratando el caso de Didac) y el grupo de Inmunología. Ambos gr</td></tr></table>comunica@vhir.org (VHIR)Mon, 30 Mar 2015 00:00:00 GMTAmics del VHIR fund the career of three young predoctoral researchers (25/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=53&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0053\2015_0053_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Marina Fortea, Marina Gabriel and Yoelsis García are the three young researchers that obtained the ‘Amics del VHIR’ grant thanks to the support of Amics del VHIR, who are the people that every month and every year donate for the research at Vall d’Hebron. Among the 23 candidates, VHIR selected these three students that will work and do their PhD at VHIR for the following 3 years: Marina Fortea holds a degree in Biology of the Universitat de Barcelona and a Master’s Degree in Biochemistry, Molecular Biology and Biomedicine of the Universitat Autònoma de Barcelona. She did an internship in the neuro-immuno-gastroenterology laboratory, led by Dr. Javier Santos and Maria Vicario, to carry out her master’s degree study on eosinophilic esophagitis; an inflammatory esophageal disease. Now, thanks to this grant, she will continue the study of this disease that causes stunted growth in children and a reduction of the esophageal caliber in adults, as well as difficulty swallowing. Marina Gabriel is a graduate in Biology, holds a Master’s Degree in Neurosciences by the Universitat Autònoma de Barcelona, and last year she was studying the hematopoietic development in the Edinburg University. On November 2012, she did and internship at VHIR and participated in the research line of neurorepair after stroke, led by Dr. Anna Rosell. In this lab, they study endothelial progenitor cells, which have a neurorepair potential and could be a new therapeutic approach for these patients. Yoelsis Garcia holds a degree in Biology of the Universidad de la Habana (Cuba), where he studied lipoproteins involved in heart diseases. On April, he will join VHIR, under the guidance of Dr. Matilde E. Lleonart, in order to work in a research project related to larynx cancer. The aim of the project is to distinguish the molecular and biological mechanisms that affect the population of cancer stem cells, which are the responsible of the bad prognosis and evolution of this tumor type. Apart from these three researchers, the Amics del VHIR also funded the first edition of the predoctoral grants of Casandra Riera and Luz Jubierre, who are now in their second year of the grant. The aim of the Institute is to repeat this call every year, and for that reason this week has started in the hospital the 3rd campaign to inform about the possibility of being Amic del VHIR. </td></tr></table>comunica@vhir.org (VHIR)Wed, 25 Mar 2015 00:00:00 GMTMessi involved with the new ad of the campaign 'Beat the silence. Beat Chagas' (24/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=52&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0052\2015_0052_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> After two years the first spot of the campaign ‘Beat the silence. Beat Chagas Disease’ was produced, FC Barcelona Foundation, Messi Foundation, The Global Health Program of the Health Catalan Institute (PROSICS) and the Vall d’Hebron Institute of Research (VHIR), with support from World Health Organization (WHO), have presented the second audiovisual of this project where, again, Messi is the protagonist. The continuation of this sensitization campaign is part of the global initiative ‘BeatChagas’ a project that aims to raise people, institutions and governments awareness of this disease. Chagas is an asymptomatic disease caused by a parasite and typically transmitted through insects (bugs), which usually live in the cracks of the houses in rural or peri-urban areas of Latin America. The new ad is about the congenital transmission of the disease (from mothers to children) to sensitize women in risk of being infected to do the detection tests. 5% of the pregnant women can transmit the disease to their children, but if these children are treated in their first months of life they become cured. The ad has been presented last Tuesday at the Camp Nou, within the medical conference ‘Bridges to beat Chagas collectively’ where many experts have been analyzing the latest news about this disease at the epidemiological, biomedical, psychosocial and management ambits, since Monday. Many patients and expert doctors from all around the world have participated in the Conference. Among them, Pere Albajar-Viñas, responsible of the control Chagas disease program of the WHO; Marcelo Leguizamón, responsible doctor of the Chagas project in the Leo Messi Foundation; Jordi Gómez, coordinator of the Medicine Topical and International Health Unite of the Global Health Program of the Health Catalan Institute (PROSICS) and researcher at the VHIR, and João Carlos Pinto, doctor specialized in Chagas, son a co-worker of Carlos Chagas (discoverer of the disease). At the institutional ambit, the vice president of the FC Barcelona Foundation, Ramon Pont, and the president of the Leo Messi Foundation, Rodrigo Messi, attended to the presentation. Gillette and the Hotel Princesa Sofía have also collaborated in the Conference. </td></tr></table>comunica@vhir.org (VHIR)Tue, 24 Mar 2015 00:00:00 GMTAround 200 people participated in the VHIR Open Day workshops for relatives (23/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=51&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Last Saturday 21st of March was a very special day for us. We opened our doors to the people we love to show them what do we do in Vall d’Hebron Research Institute (VHIR). Throughout the morning, around 200 relatives of our colleagues attended one of the 12 guided visits scheduled, after previous enrolment. All visits started in the Collserola building with a funny video played by children of VHIR workers. In the video they explained the important work performed by VHIR researchers, and show the facilities of the center. All tours passed through any of the following workshops organized by VHIR researchers: “Nanoparticles and tumor tissues”, organized by researchers of the CIBBIM-Nanomedecine in Drug Delivery and Targeting group “What do cells look like and how can we recognize their nucleus?”, organized by researchers of the Gynecology and Urology Biomedical Research Group. “What do lungs look like under a microscope?", organized by Dr. Maria Jesús Cruz, head of the Pneumonology group.&nbsp; “Extract DNA from strawberries!”, organized by Rosa Arjona, from the High Technology Unite. “¿What does it look like in the microscope?”, organized by Dr. Rosa Prieto, from the High Technology Unit. “Synthesis and applications of inorganic nanoparticles in diagnosis and detoxification”, organized by Dr. Víctor Puntes, head of the Nanoparticles and Pharmacokinetics group. “Murine models for investigating diabetes and obesity”, organized by Dr. David Martínez, researcher in the</td></tr></table>comunica@vhir.org (VHIR)Mon, 23 Mar 2015 00:00:00 GMTNew hope against growing threat of antibiotic resistance (19/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=50&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0050\2015_0050_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Infectious Diseases group at Vall d’Hebron Research Institute (VHIR), the Infections and Antimicrobial Therapies group at the Institute for Bioengineering of Catalonia (IBEC) and the research group in Mycobacteria at the Universitat Autònoma de Barcelona (UAB) have identified a molecule with huge potential as a new type of antibacterial agent. The finding has been published in PlosOne. “During the course of infection, bacteria need to multiply inside the body, and they require active DNA synthesis to multiply”, says Dr. Eduard Torrents, who heads the Bacterial Infections: Antimicrobial Therapies group at IBEC. “By targeting the key enzyme that allows this to happen, we can inhibit the growth of various types of undesirable and disease-causing bacteria”. The molecule, known as M-HA, works as a ‘radical scavenger’ compound to inhibit ribonucleotide reductase, an essential enzyme in DNA replication and repair. It also demonstrates low toxicity in eukaryotic cells, which heralds a great improvement on existing RNR-inhibiting drugs, which are mostly used against cancer or viruses and are too toxic to be used as antibacterials. Access to effective antibiotics is essential in all health systems. Their use has reduced childhood mortality and increased life expectancy, and they are crucial for invasive surgery and treatments such as cancer chemotherapy and organ transplants. The most recent World Economic Forum Global Risks reports have listed antimicrobial resistance as one of the greatest economical and societal risks threats to human health. In addition to increased resistance to existing agents, there is a lack of new antibiotics in development, according to a study by the European Medicines Agency. The projection of 10 million deaths a year by 2050 is greater than the current annual death toll from cancer. It is in that context that Dr. Joan Gavaldà from VHIR states that <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color: #555555; background-color: transparent; text-decoration: none</td></tr></table>comunica@vhir.org (VHIR)Thu, 19 Mar 2015 00:00:00 GMTVall d'Hebron participates in the activities of the Brain Awareness Week (18/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=49&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0049\2015_0049_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Professionals from Vall d’Hebron University Hospital, together with researchers from the Neurotraumatology and Neurosurgery research group at VHIR, participate once again in the Brain Awareness Week, organized by the Institut Municipal d’Educació de Barcelona from the 16th to the 22nd of March. Students from the Institut Consell de Cent visited the center this Wednesday in order to know at first hand the task carried out by the professionals. The aim of the workshop, entitled 'Viu de prop el problema: coneix les causes i parla amb el malalt', is to explain the traumatic brain consequences that people can suffer after surviving a traffic accident. In this session, students learned the mechanisms involved in traumatic brain injuries, what happens in the acute phase of this event, and which are the symptoms and the social and familiar consequences that these accidents cause. During the visit, students visited the Intensive Care Unit of the Neurotraumatology and Rehabilitation service, where they saw and heard about the experience of some patients. Apart from this activity, Dr. Àlex Rovira, head of the Magnetic Resonance and Neuroradiology group, also participated in the Brain Awareness Week with a talk about the historical development of the imaging techniques of the brain in medicine. One week to raise awareness on science 21 research centers located in Barcelona collaborate with the activities of the Brain Awareness Week, in which are participating 1.200 students from 26 schools and high schools of the Catalan capital. The Brain Awareness Week is held in more than 80 countries and is promoted by the Dana Alliance for Brain Initiatives. </td></tr></table>comunica@vhir.org (VHIR)Wed, 18 Mar 2015 00:00:00 GMTAdolescents with ADHD resistant to medication reduce symptoms after a psychological treatment in group (17/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=47&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0047\2015_0047_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the group of Psychiatry, Addiction and Mental Health of the Vall d'Hebron Institute of Research (VHIR) have reduced the symptoms of adolescents medicated for Attention Deficit Hyperactivity Disorder (ADHD) using a cognitive-behavioral group therapy. The results of psychological treatment have been published in the most prestigious journal in the field of youth psychiatry, the Journal of the American Academy of Child and Adolescent Psychiatry. The study led at VHIR was held at the Vall d'Hebron University Hospital and the Hospital Clinic between April 2012 and May 2014 on 119 adolescents between 15 and 21 years, treated with either of the two drugs used with ADHD. All patients continued with medication, but about half received cognitive behavioral therapy, and the rest simply continued with routine visits to psychiatry. At the end of the psychological treatment, which consisted of 12 group sessions of one hour a week, the symptoms of the disorder were reduced in these young people. "With the cognitive behavioral group treatment we can reduce the symptoms of adolescents with severe ADHD, especially those regarding the inattention and impulsivity," said Dr. Josep Antoni Ramos Quiroga, study director and program coordinator of ADHD at Vall d'Hebron University Hospital. According to the VHIR researcher, psychological treatment makes sense because "medication can increase the ability of patients to maintain and make better care and reduce impulsivity; but the drug does not help them get organized enough". The aim of the psychological treatment was precisely to provide teenagers strategies and skills to compensate for their symptoms, whether cognitive or behavioral. 12 sessions were divided into two modules, directed by Raquel Vidal, Rio Hortega researcher at VHIR at the time of the study and clinical psychologist at the Vall d'Hebron University Hospital. In the first module she offered strategies to control impulsivity: self-control techniques, identification of triggers and warning signs to regulate anger, interpersonal skills to accept criticism, handling frustration and motivational strategies. On the other hand, in the second module she focused on techniques for maintaining attention: strategies for planning, problem solving and decision making, ability to postpone events and skills to reduce distractions and distracting thoughts. All the techniques used were collected in the first part of the book "Cognitive-behavioral Treatment for Adolescents with ADHD and cannabis, published in 2014. ADHD is a neurodevelopmental disorder that affects between 3 and 5% of the population during childhood, and remains more than half of the patients during adolescence. The most common symptoms are inattention, disorganization, lack of impulse control, emotional instability, hyperactivity, and even oppositional defiant symptoms. Persistent ADHD in adolescence is associated with a poor academic performance, difficulties in maintaining relationships, drug abuse and risk driving and sex. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: </td></tr></table>comunica@vhir.org (VHIR)Tue, 17 Mar 2015 00:00:00 GMT42 km of effort to promote research (17/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=48&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0048\2015_0048_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Sport helps health and also research. One example was the 37th Zurich Barcelona Marathon held on Sunday. Over 42 km race, that Dr. Cristina Solé and a group of parents of the AMPA of the Virolai School proposed achieve in order to raise money for research. Dr. Cristina Solé, who investigates about Lupus Disease in the Systemic Diseases research group of Vall d'Hebron Research Institute (VHIR), raised 1,600 Euros that will be invested in research about this serious disease of the immune system. Specifically, the money will serve to fund some research projects of the internal medicine research line, in Lupus, at VHIR, a group led by Dr. Jose Ordi-Ros which has the collaboration of the Catalan Lupus Foundation and the A. Bosch Foundation. This research group works hard to find ways to treat this disease, that only in Catalonia, is affecting more than 6,000 people. With a similar purpose, a group of parents of the AMPA of the Escola Virolai also ran this marathon, but in this case, with the aim of raising funds for research in pediatric liver transplants. They raised 2,410 Euros, long surpassing the figure of 1,200 Euros that was proposed in the beginning. In both cases the challenge was a success: they all could finish the marathon and raise the money they had purposed. We congratulate them for the effort and their altruism! </td></tr></table>comunica@vhir.org (VHIR)Tue, 17 Mar 2015 00:00:00 GMTSuccess of the 4th Gut Microbiota for Health Summit (16/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=46&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0046\2015_0046_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On 14 and 15th March was held in Barcelona the 4th Gut Microbiota for Health Summit. The event brought together more than 300 international experts (including doctors and nutritionists) and has served to expose the latest findings in the investigation of the intestinal microbiota and its importance to human health. The role that bacteria inhabiting our gut have is just beginning to be known, but it is becoming evident that there is a relationship between our microbiota and our health. "It's a fascinating and very promising area of scientific research", said Dr. Francisco Guarner, member of the physiology and pathophysiology group at VHIR and chairman of the scientific committee of the Summit. Dr. Guarner explained there are disorders that may be associated with certain intestinal microbiota, such as obesity, certain metabolic and autoimmune disorders (such as celiac disease and food allergies) or some cancers. In the Congress, organized by the UEG (United European Gastroenterology Federation) and the AGA (American Gastroenterological Association), various topics within the field of intestinal microbiota were exposed, but perhaps one of the most important was what might be the consequences of the use of oral antibiotics for the intestinal microbiota. "Every time we take antibiotics by mouth is like a forest fire in our gut occurs. We can rebuild this ecosystem, but it will take time and will never be what it was", explains Dr. Fernando Azpiroz, president of the Summit organizing committee and head of the physiology and pathophysiology group at VHIR. Other topics discussed were the relationship between gut microbiota and development of some psychiatric or behavioral disorders, such as autism; the implication of some intestinal bacteria in the cancer of colon and liver; how cant he type of delivery or the breastfeeding may affect the intestinal microbiota of children (and therefore their health), or what was the microbiota of our Paleolithic ancestors like. The Summit also discussed the use of prebiotics and probiotics to fight disorders of the intestinal flora and as a treatment for certain diseases, and the importance of a balanced diet to protect the body from many diseases. "There has been a lot of interaction between scientists and clinicians, and much discussion about what we know and what these issues can contribute in the future to improve medical practice"<span style=" font-size: 8pt; font-family:</td></tr></table>comunica@vhir.org (VHIR)Mon, 16 Mar 2015 00:00:00 GMTVHIR's Innovation Contest arrives to other research centers of Catalonia (12/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=36&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0036\2015_0036_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Today March 12 has been opened the 2nd Innovation Contest. In this editiion the great news is that, after the success of the first edition, there will be participants from Hospitals and research centers belonging to ICS, Hospital research centers of Catalonia accredited by ISCIII and Hospital research centers of Catalonia that are part of ITEMAS. Organized by VHIR in collaboration with ACC10 and ROCHE Diagnostics, the contest aims to promote the innovation that comes from hospitals and their associated research centres. With this initiative we aim to raise awareness about health innovation projects, in order to attract investors and companies. At the same time we support the projects in the first stages, where we will assess the technical viability and the market. In addition, we want to award the professionals for their innovation capacity. VHIR's Director, Dr. Joan Comella, opened the contest highlighting that "it's a unique opportunity for doctors and researchers to innovate in their field, thanks to the companys and first level tutors that will help us in this experience." He thanked the technical committee, the team of tutors and teachers for supporting this second edition. The Head of Projects and Innovation of Roche Diagnostics, Dr. Carlos Manchado, has explained why they bet for this contest, which, according to the Innovation Director at the Institute of Catalan Health (ICS), Dr. Navas, "is a model that ICS wants to estimulate". Furthermore, the Manager of Technology Transfer of ACCIÓ, Ana Simon, said that "VHIR is a reference in innovation and for this reason ACCIO encourages all the Catalan hospitals and research projects to participate." Dr. Gabriel Capellà, who presided the event as responsible for research and innovation at the Catalan Health Department, also encouraged the public institutions to bet for the innovation, as VHIR does. Closing the opening, Montserrat Llinàs presented the situation of the project 'Automatización de lavoados vesicales contínuos', awarded in the first edition of the contest. She was presented by Maria Ángeles Barba, head of Nursing at Vall d'Hebron. Angel Alonso, general manager of Vecmedical, explained why and how this company is helping this project as an industrial partner. HOW TO APPLY <p style=" text-align: left; text-indent: 0px; padding: 0px 0px 0px 0px; margin:</td></tr></table>comunica@vhir.org (VHIR)Thu, 12 Mar 2015 00:00:00 GMTThe Gynecology and Urology Biomedical Research groups collaborate with scientific teaching at the Institute 4Cantons (11/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=44&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0044\2015_0044_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The groups of Biomedical Research in Gynecology and Urology of VHIR have initiated an educational action in collaboration with the Institute Quatre Cantons (4Cantons) of Poblenou, Barcelona. This is a public secondary school with a great teaching quality and an innovative method, and therefore it was awarded the prize Ciutat de Barcelona in Education. His pedagogical project is based on finding centers of interest and introduce different subjects through them, using what they call globalized work. During this semester, the Gynecology and Urology Biomedical Research groups have offered a globalized work focused on the study of gynecologic cancers. They have proposed students to design a tool that helps researchers to investigate animal models, using their knowledge in design and digital printing. More specifically, the aim for the students is to design a mechanism for dispersing human tumors, reducing its size to introduce them in mice and investigate. During these four weeks the collaboration lasts, researchers and students meet at the premises of 4Cantons Institute to have lessons related to cancer and at the VHIR, to know the center, see in situ what the reseearch is and to do experiments. This collaboration is possible thanks to the interest that all members of the research group have for teaching, and is included within the overall objective of bringing science to society. As one of the researchers of the Ginecology group said, Dr. Anna Santamaria: "For our groups it has been a very enriching experience that has allowed us not only to bring our research to adolescents of this institute, but also encourage the researcher spirit that surely is inside some of them! ". Students are also really enjoying the experience and highlight the interest that has taken them to see up close how a prestigious research laboratory works. They tell us they have learned a lot about cancer and physiology of the body, and add: "and the best of all is that we have not only learned but may have helped research". </td></tr></table>comunica@vhir.org (VHIR)Wed, 11 Mar 2015 00:00:00 GMT'Music has an amazing ability to thrill' (09/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=40&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0040\2015_0040_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr Miguel Vila, head of the neurodegenerative diseases group, talked about his two passions, music and research, in an interview with la Gaceta Médica. This researcher of Parkinson's Disease at Vall d'Hebron Institute of Research (VHIR) plays for many years the violin and is a member of the medical world orchestra, that organize charity concerts over the world. In the interview in la Gaceta Médica he said that "music has an amazing ability to thrill, as for example, people with Alzheimer's disease, who can’t recognise people of their family, can feel thrilled with the music they liked". In his research field, Dr. Vila is optimistic about the chances of finding, in a not so distant future, a cure for Parkinson "as neurodegenerative diseases share common mechanisms, progress in one of these diseases contributes to the advancement of the rest. In particular, in the field of Parkinson's disease, the research is approaching to the early detection and I think that sooner or later, we will get a cure." </td></tr></table>comunica@vhir.org (VHIR)Mon, 9 Mar 2015 00:00:00 GMTVHIR coordinates a project to obtain stroke biomarkers (06/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=39&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0039\2015_0039_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The neurovascular diseases group at VHIR, led by Dr. Joan Montaner, will coordinate in the next two years the project 'Device point of care of stroke diagnostic with plasmatic biomarkers: 2-stroke-chip (TECH-StrokeChip2), funded by Instituto de Salud Carlos IIII (ISCIII). TECH-StrokeChip-2 counts with the participation of several Catalan hospitals: Vall d'Hebron, Josep Trueta, Joan XXIII, Germans Trias i Pujol, Bellvitge, Parc Taulí and Verge de la Cinta. The target of the project is to obtain panels of biomarkers for its clinical application in ictus and its introduction in a Point of Care (POC) device to be applied in the clinical practice in months or few years after the end of the study. In order to get it, they will use the serum bank of patients generated by Dr. Montaner's group, where will screen aptamers to find new biomarkers to diagnose stroke. Together with other biomarkers already identified by the Neurovascular diseases group in previous multicenter studies with the same participants hospitals, the project wants to obtain panels of biomarkers with predictive capacity for diagnostics and prognostics of stroke patients. These candidate biomarkers are integrated in a device of quick mesure based in electrochemical biosensors that will be developed at Dr. Eva Baldrich's lab in the Nanomedicine area, and will be proved in a pilot trial in some of the hospitals members of the project.&nbsp; "With this study we should be able to transfer to the patient a device that could predict diagnostics and prognositcs of stroke, which would be a major advance for all the people who's suffering this disease", comments Dr. Montaner. All the participants of TECH-StrokeChip2 had a kick-off meeting at VHIR recently which served to initiate the work that could led them to get the goals in the next two years. </td></tr></table>comunica@vhir.org (VHIR)Fri, 6 Mar 2015 00:00:00 GMTGreat success of the 1s Innovation Day organized by ICS (05/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=38&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0038\2015_0038_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The experience “Preoperatorio online, enfermería y anestesia”, presentaded by Domingo Blanco, head of the Anesthesia Service at Viladecans Hospital has been awarded as the Best Innovative Experience of Catalan Institute of Health (ICS). This project develops a presurgery circuit, led by the nurse team at the Anesthesia Service, using the TIC to save duplicity of complementary trials and reduce movements of the patients. More than 600 people attended the 1st Innovation Day of ICS, that during all the morning have listened the 10 finalist proposals out of 388 accepted. 3 of them were from VHIR: "Neuroprotección como tratamiento de la retinopatía diabética: del modelo experimental al ensayo clínico", led by Dr. Rafael Simó, head of the Diabetes research group at VHIR and one of the winners of the first edition of VHIR Innovation Contest last year. "Desarrollo de una nueva plataforma de subtipificación de alta resolución y detección de infecciones mixtas y mutaciones de resistencia del virus de la hepatitis C", led by Dr. Joan Ignasi Esteban Mur, from the liver diseases group and "Programa de rehabilitación cardíaca y prevención secundaria en enfermos con síndrome coronaria aguda atendidos en el HUVH", led by Dr. Xavier Armengol, from the cardiocirculatory pathology group completed the presence of Vall d'Hebron researchers. On March 12 it will be the Opening of the Second VHIR innovation contest, that in this edition includes participants from other centers at ICS, Catalan centers of ITEMAS and Catalan centers accredited by ISCIII. </td></tr></table>comunica@vhir.org (VHIR)Thu, 5 Mar 2015 00:00:00 GMTLast goodbye to Dr. Jordi Xercavins (04/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=37&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0037\2015_0037_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Jordi Xercavins, former head of the Gynecology of Vall d'Hebron University Hospital left us on Monday. The farewell ceremony will take place today at 11:30h at the Monastery of Sant Cugat. We express our sincere condolences to his family and friends at this difficult time, as well as all professionals who worked with him over these years. Jordi Xercavins Montosa was head of Gynecology from 1993 until 2013, when he retired and became a senior consultant and Professor of Obstetrics and Gynaecology of the Universitat Autònoma de Barcelona (UAB). Until 2013 he also presided the Section of Gynecology Oncology and Mammary Pathology of the Spanish Society of Gynecology and Obstetrics. Beyond the great contributions he made in the Gynecology Hospital, such as the creation of the various subspecialities that are still valid, and the commitment to research and teaching, Dr. Xercavins always noted for his great human qualities and for always showing empathy towards all that surrounded him. Rest in peace. </td></tr></table>comunica@vhir.org (VHIR)Wed, 4 Mar 2015 00:00:00 GMTDr. Pedro Brugada talks about the syndrome that has his last name (02/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=32&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Doctor Pedro Brugada, responsible of the Heart Rhytm Management Centre of the Universitair Ziekenhuis in Brussels (Belgium), has visited the researchers and cardiologists at the Vall d’Hebron University Hospital to teach the session called ‘Past, present and future of the Brugada syndrome’. The physician, born in Banyoles (Girona), discovered in 1992 an alteration in the electrocardiogram of patients that had had a sudden death. Sometime later, thanks to the help of his brothers, also prestigious cardiologists, they named this particular lethal cardiac arrhythmia as ‘Brugada syndrome’. About this syndrome he spoke in the session organized by the Cardiology Service and in a short video where he explains why it isn’t an illness and what its prevalence is. During the visit at the center, Dr. Brugada also had time to discuss with the cardiologists at Vall d’Hebron some of the cases of patients admitted in the hospital. </td></tr></table>comunica@vhir.org (VHIR)Mon, 2 Mar 2015 00:00:00 GMTDr. Ribó presents at the MWC advances in the follow up of stroke patients (02/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=34&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0034\2015_0034_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Marc Ribó, member of the research group in neurovascular diseases at VHIR and neurologist at the Ictus Unit of the HUVH, has been at the Barcelona Mobile World Congress (MWC) presenting, together with the Fundación Vodafone Spain, the new advances in the follow up of stroke patients at home under the control of a medical team Visited by the Major of Barcelona, Xavier Trias, and the Catalan Minister for Enterprise and Employment, Felip Puig, Dr. Ribó has explained in the stand of Vodafone the news methods that will improve the situation of stroke patients during the follow up phase at home. Thanks to this innovation, the doctor will send follow up exercises personalized and in multimedia format (text, picture and video depending on the patient), who will be able to do it from home. Doctors will supervise the evolution with videos recorded during the exercises made by patients. This new improvement in the project, that is still being validated, is a step forward of the Global Tele Rehabilitation System (GTRS), also promoted by VHIR with the help of Fundación Vodafone Spain, that finished with great results after one year and a half of testing applications. </td></tr></table>comunica@vhir.org (VHIR)Mon, 2 Mar 2015 00:00:00 GMTVHIR, committed to the research on rare diseases (27/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=33&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0033\2015_0033_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The 28th of February is Rare Disease Day with the theme “Day by Day, Hand in Hand”, to raise awareness about this diseases that, only in Spain, affect more than 3 million people. The Vall d’Hebron Institute of Research (VHIR) wants to join in the campaign to give patients and families a feeling of hope and the possibility of a positive change. Also, in Spain, the Spanish Federation of Rare Diseases (FEDER) has launched a campaign to commemorate the day and make these diseases visible. In consists on taking a photo with a green mark on the cheek and sharing it, as has done VHIR’s director, Dr. Joan Comella, and some of the researchers that work in rare diseases. They are Dr. Anna Meseguer, that together with Dr. Ariceta lead research work on Dent’s syndrome and&nbsp; hypomagnesaemia; Dr. Ramon Martí, in the area of mitochondrial diseases; and Dr. Cristina Solé, that works on lupus. The fight against rare diseases is one of VHIR’s pillars, where nearly 200 of these diseases are investigated, from 26 different clinical areas. Doctors, predoc and postdoc researchers, nurses and technical staff make a total of more than 350 professionals that dedicate part of their day by day to move forward in the knowledge of these diseases and finding treatments to increase quality of life of patients and cure them. For a better management of these diseases, the Vall d’Hebron University Hospital is starting up a new and integrated model of patient care, in which research has a key role. With the new system, most of these patients will be able to be visited in a module of the Rare Diseases Unit, by multidisciplinary teams trained in research and clinical treatment. In addition, the new model allows the possibility of a follow up and treatment of patients, from childhood to adulthood. The goal is that specialists can “reach an understanding through a case management system” to schedule visits with the frequency that is required in each case. This unit would be integrated in the Genetics clinical and molecular area, directed by Dr. Eduardo Tizzano, head of the Genetics Medicine group at VHIR. Among the rare diseases investigated at Vall d’Hebron, there are systemic diseases, such as lupus erythematosus, scleroderma and Sjörgen’s syndrome; pediatric neurology diseases, like mitochondrial diseases, lysosomal storage disorder or neuromuscular disorders; and other such as cystic fibrosis, Marfan syndrome, immunodeficiency diseases, spina bifida, ALS, or Dent’s disease. </td></tr></table>comunica@vhir.org (VHIR)Fri, 27 Feb 2015 00:00:00 GMTThe Dexeus Foundation has awarded a grant to a project about ovarian cancer led by VHIR (26/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=31&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0031\2015_0031_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Biomedical Research Gynecology group at Vall d'Hebron Institute of Research (VHIR) has been awarded the grant of Gynecologic Oncology and Mammary by the Fundación Dexeus Salud de la Mujer, for the project "Salivaomics; innovative strategy to improve the early diagnosis of ovarian cancer". The aim of the project, led by Dr. Silvia Cabrera, is to identify a set of biomarkers to develop a diagnosis method for the ovarian cancer at an early stage by a saliva sample. According to the researcher, “the existence of diagnostic methods to detect ovarian cancer in the early stages of the disease would radically change the rate of healing of patients." To carry it out, VHIR researchers will do a massive sequencing of the free RNA fraction present in the saliva samples from patients in early stages of the disease (I-II) and in advanced stages (III-IV). Samples will be collected in the operating room of Gynecology of the Vall d'Hebron University Hospital, where women who undergo surgical resection, the last step in the diagnostics of ovarian cancer, regularly spend. The project has received a 3,000 Euros grant, is expected to last two years and has the collaboration of Dr. David T. Wong, world leader in the field of the salivaomics in the Center for Oral/Head and Neck Oncology Research of UCLA School of Dentistry, Los Angeles (USA). The aim is to develop, in a long-term, a diagnostic and/or a screening test, involving an industrial partner. It’s essential to develop early detection methods for the ovarian cancer because nowadays the 80% of the patients are diagnosed on the advanced stages of the disease (III-IV), where the rate of healing, in a 5 years term, is between the 30-20%, and however, when the disease is detected in the early stages (I-II), the rate increases to the 90-70%. The current method for ovarian cancer diagnosis is based on the following evidence: a pelvic exam, in which the gynecologist can tact the size and consistency of the ovaries; the determination of the levels of serum marker CA125, which is very high in the cases of advanced stages but only in the 50% of the patients in initial stages; an abdominal ultrasound, to detect suspicious masses in the ovaries; and at the end, the surgical resection, which is strictly necessary to confirm the disease by the histological study of the mass. In this last step, the surgery, only 1 in 10 women operated is diagnosed, at the end, of ovarian cancer. According to the Spanish Association Against Cancer, annually in Spain over 3,000 cases are diagnosed. Given this situation, and based on the scientific experience of the groups involved in biomarker research in biofluid samples (non-invasive and minimally invasive), VHIR researchers will conduct this project grant from the Dexeus Foundation with the aim of improving the overall survival of ovarian cancer. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #</td></tr></table>comunica@vhir.org (VHIR)Thu, 26 Feb 2015 00:00:00 GMTInternational acknowledgment for nursing Vall d'Hebron Hospital (25/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=30&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0030\2015_0030_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d'Hebron University Hospital has been recognized as a Centre Committed to Excellence in Nursing Care, an accreditation that recognizes the high quality of nursing noting the commitment to put up good practice guidelines developed by the prestigious Registered Nurses Association of Ontario (RNAO), the Ontario Nurses' Association, with more than 60,000 affiliates, and a genuine international reference in this professional field. The RNAO has created a program called Best Practices Spotlight Organizations (BPSO) dedicated to the implementation of these guidelines, coordinated in the State by the Investen-ISCIII. In this program, Vall d'Hebron is the first center of Catalonia in achieving this accreditation, which will also receive seven other hospitals in the state. So far, they have succeeded centers worldwide as the Mount Sinai de Toronto or St. Joseph’s Health Care London. . The University Hospital Vall d'Hebron has achieved this accreditation after three years of hard work that has benefited from the involvement of more than 150 professionals from 16 units of the three areas where the hospital is divided. By participating in this program there have been implemented and evaluated the impact of two clinical practice guidelines: Care and ostomy management and Prevention of falls and injuries from falls in old people. The two guides implemented born of care research. It is shown that nursing best practice not only improve care for patients and but contribute to cost savings in the health system. Nursing also investigates in the Health Care research group at VHIR, led by Dr. Carmen Fuentelsaz. </td></tr></table>comunica@vhir.org (VHIR)Wed, 25 Feb 2015 00:00:00 GMTUse of massive genome sequencing to identify pathologic mutations (24/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=28&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0028\2015_0028_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> How work and how can be applied the massive sequencing techniques into biomedical research? Researchers from Vall d’Hebron Institute of Research (VHIR) and the Centre Nacional d’Anàlisi Genòmica (CNAG) answered this question at the course ‘Identification and analysis of sequence variants in sequencing projects: fundamentals and tools’, hosted at VHIR on February 11 and 18. The latest massive sequencing techniques belong to the field of genomics and are applied to biomedical research and for the diagnosis of patients. These techniques are able to identify the differences in the genome of individuals, and are used with the aim to promote the most accurate diagnosis, choose the best treatment or give genetic counseling on hereditary diseases. About these techniques talked Dr. Xavier de la Cruz, head of the Translational Bioinformatics group at VHIR, and Casandra Riera, researcher of the same group, and doctors Ivo Gut, Sergi Beltran and Sophia Derdak from CNAG. All the presentations of the course are available on Slideshare: Interpretation of sequence variants in the biomedical environment: what should we take into account, by Xavier de la Cruz Using and combining the different tools for predicting the pathogenicity of sequence variants, by Casandra Riera <p style=" text-align: left; text-indent</td></tr></table>comunica@vhir.org (VHIR)Tue, 24 Feb 2015 00:00:00 GMTVall d'Hebron Market rises 1,140€ for research in cardiovascular diseases (24/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=29&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0029\2015_0029_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The sellers of the stands of the Vall d’Hebron Market have raised 1,140€ with the solidarity 2015 calendar, sold by 1 euro. The promoters of the initiative have given today the funds raised to Dr. David García Dorado, head of the research group on Cardiovascular Diseases at Vall d’Hebron Institute of Research (VHIR). With this action the market workers wanted to do their bit in heart diseases research, as it causes thousands of deaths every year. The calendars were drown by Mario Tarragó and designed by Jordi Santamaria. The Cardiovascular Diseases group works in prevention, diagnosis and treatment of heart diseases. The researchers also coordinate actions in sanitary education, healthy lifestyle promotion and create new diagnosis and therapeutic tools and new care systems. </td></tr></table>comunica@vhir.org (VHIR)Tue, 24 Feb 2015 00:00:00 GMT"I wish music could tame cancer" (19/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=25&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0025\2015_0025_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Interview posted in the blog '30 anys, 30 veus' by the Catalan Institute of Health (ICS): Per a Josep Roma, tant en la música com en la lluita contra el càncer, cal posar-hi passió. Tot i que la seva faceta de músic va quedar aparcada quan va arribar a la universitat per estudiar medicina, mai ha deixat de tocar. Es defensa a la perfecció amb diversos instruments: el saxo, el clarinet, la tenora i fins i tot el tible, un instrument tradicional semblant a l’oboè. Quan surt del laboratori, troba temps per participar en concerts solidaris i actuacions d’estils musicals tan variats com la cançó francesa o el rock i, també, per cercar la “genètica de les notes”. Voleu saber què significa aquesta denominació? I quan la va “explicar”? Continueu llegint! Lloc de treball. Laboratori de Recerca Traslacional del Càncer en la Infància, Servei d’Oncologia i Hematologia Pediàtrica, Vall d’Hebron Institut de Recerca, Hospital Universitari Vall d’Hebron, Barcelona. Tens molts estudis de música… És cosa de família o una iniciativa pròpia? Bé, vaig fer estudis de música des de molt aviat i, realment, m’interessava molt la música des de molt petit. Probablement hi va influir el fet que el meu pare fos músic, també. Recordo que va arribar a les meves mans un saxo de joguina i em vaig posar a tocar cançons de seguida, tot i que era un instrument de plàstic. Els meus pares van quedar-se una mica sorpresos del que podia treure d’aquell instrument tan rudimentari i va ser el que els va fer decidir a apuntar-me a estudiar música immediatament, tot i que encara era molt petit: devia tenir 6 o 7 anys. El teu currículum musical és tan important com el professional. Quines inquietuds mouen un músic a formar part de grups amb estils musicals tan variats com la música tradicional, el rock, la cançó francesa o, fins i tot, a arribar a acompanyar, en alguna ocasió, cantants de primera línia, com ara la Núria Feliu? No crec que el currículum musical sigui tan gran, no m’hi he pogut dedicar gaire. La música, com tot, demana molt de temps d’estudi i, a partir de cert nivell, és necessari dedicar-hi moltes hores al dia. Al principi, em vaig agafar la carrera de música molt seriosament i compaginava sense gaires problemes la música i els estudis, però quan vaig arribar a la universitat l’exigència en els dos casos ja era massa gran per seguir amb les dues coses al cent per cent. Cap als darrers anys de carrera, vaig anar relaxant el tema de la música per anar-me centrant, gradualment, més en la ciència. I sí, he anat fent una mica de tot dintre de la música; és un privilegi haver-ho pogut fer perquè realment he après de totes les experiències i m’ho he passat molt bé en tots els casos. Tinc la sort que tots els estils de música m’agraden. Sempre dic que, de fet, només n’hi ha dos, d’estils: la música bona i la dolenta. Has participat en un congrés de pediatria on has ajuntat les seves dues facetes en una xerrada musical: “La genètica de les notes”. Quin plantejament et feies i què buscaves despertar entre els assistents? Això pretenia ser una sorpresa i, de fet, ho va ser perquè molta gent no tenia ni idea que jo toqués cap instrument ni, molt menys, que ho anés a fer en aquell moment. A més, l’any anterior havia fet una xerrada científica en el mateix congrés o sigui que poca gent es pensava qu</td></tr></table>comunica@vhir.org (VHIR)Thu, 19 Feb 2015 00:00:00 GMTDr. Josep Gámez participates in the 3rd Catalan Ataxias meeting (18/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=24&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0024\2015_0024_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Gámez, head of the Peripheral Nervous System group at Vall d’Hebron Institute of Research (VHIR), was one of the lecturers of the III Catalan Ataxias meeting, organized by the Catalan Association for Ataxias, on January in Barcelona. VHIR researcher talked about the usefulness of functional rating scales for the assessment and follow-up of ataxias, which are a group of rare diseases characterized by a progressive spinal and/or cerebellar degeneration. The participants also discussed the latest studies and clinical trials on these diseases. Some of them were researchers and neurologists from Catalan hospitals such as Hospital Universitari Germans Trias i Pujol, Hospital Universitari de Bellvitge, Hospital Clínic, l’Hospital Sant Joan de Déu and Hospital Josep Trueta. The meeting was a perfect occasion for networking between patients, their relatives, researchers and clinicians. According to the Catalan Association for Ataxias, nearly 900 people are affected in Catalonia. Patients with ataxia use to have difficulties related to coordination, balance, speech, and can suffer heart problems.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Wed, 18 Feb 2015 00:00:00 GMTVHIR researchers develop a methodology that will help doctors choosing the most efficient treatment for hepatitis C (16/02/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=23&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0023\2015_0023_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from Vall d’Hebron Research Institute (VHIR) have developed a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations. “We are going one step further in personalized medicine, because thanks to this new system we can decide which is the treatment with greater chances of success in each patient”, reports Dr. Rafael Estaban Mur, head of the Hepatic Diseases group at VHIR and responsible of the Department of Internal Medicine and Hepatology at Vall d’Hebron University Hospital. The two commercial available genotyping methods can only identify the main genotypes and two out of the 67 subtypes of the virus. As the efficacy of new treatments depends on the subtype, physicians do not have tools to choose the most efficient treatment. The study, published in the Journal of Clinical Microbiology, is a collaboration between all the members of the Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Roche and ABL. It is funded with the CDTI MINECO IDI 20110115. Comparison with the current technologies The scientific community has achieved major steps in the study of hepatitis C, especially in the development of new inhibitors, such as sofosbuvir and simeprevir. The combination of these new drugs has reached cure rates up to the 90 per cent in controlled clinical trials, without using the classic treatment of interferon (which causes many side effects such as depression and fever). However, the response to the new antiviral inhibitors is different in each genotype and subtype of the HCV virus. For that reason, Dr. Esteban Mur alerts that <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', </td></tr></table>comunica@vhir.org (VHIR)Mon, 16 Feb 2015 00:00:00 GMTThe 3rd DiR-Guàrdia Urbana race will raise funds for research in child cancer (12/02/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=22&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0022\2015_0022_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The third edition of the DiR-Guàrdia Urbana race will take place in the Avinguda Diagonal, in Barcelona, on May 31st. Participants will run 10km of the entire Diagonal, with two messages: “for you maybe is just a race, but for them is their life” and “run and help us to investigate for children with cancer”. Part of the funds collected in the race will be donated to the Translational Research in Child Cancer group at Vall d’Hebron Institute of Research (VHIR). The race will start at 8.30 AM at Palau Reial and the finish line will be located at Passeig Garcia Faria. Registrations are already open on www.dir.cat and in any of the gyms of the group. The mission of the Translational Research in Child Cancer group is to improve the diagnosis and treatments available for these diseases. </td></tr></table>comunica@vhir.org (VHIR)Thu, 12 Feb 2015 00:00:00 GMTInterarts and VHIR publish the results of the DECIDES ESPAÑA project's assessment (10/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=21&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0021\2015_0021_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> DECIDES ESPAÑA has just published on its website the Assessment on access to sexual and reproductive health rights for women in reproductive age of migrant origin in Spain, and an operational guide. One of the most important results of this assessment, in which have participated members of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR), is the suitability of developing new educational and informative materials on affective sexual and reproductive health integrating the approach of equity, gender and cultural specificities. The study, presented in Barcelona on the 18th of December, 2014, is part of the activities within the project DECIDES ESPAÑA, implemented by Interarts and VHIR to improve equity in the access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. The assessment has been developed by a multidisciplinary group of professionals under the leadership of the Unidad de Salud Internacional Drassanes-Vall d'Hebron (PROSICS Barcelona). The materials suggested in the assessment will also be developed within the framework of DECIDES ESPAÑA, co-funded by the Financial Mechanism of the European Economic Area (EEA Grants) which aims at contributing to the reduction of economic and social inequalities, and strengthening links between donor (Iceland, Liechtenstein and Norway) and beneficiary countries (17 EU Member States). The Plataforma de ONG de Acción Social is the Operational Unit of the Programa de Ciudadanía Activa (Active Citizenship Programme) endowed with EUR 4.6 million to support the contribution of NGOs to social justice and sustainable development. Follow on Twitter: @Ciudadania_Act #CiudadaníaActiva and Facebook: Programa de Ciudadanía Activa. </td></tr></table>comunica@vhir.org (VHIR)Tue, 10 Feb 2015 00:00:00 GMTThe AECC grants a study on child cancer at VHIR (09/02/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=3&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0003\2015_0003_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Spanish association for cancer research (AECC) in Catalonia gave, on Thrusday, 5 one of the 5 grants of the institution to Dr. Aroa Soriano, member of the Translational Research in Child Cancer group at Vall d’Hebron Institute of Research (VHIR). Her study aims to determine the contribution of the extracellular kinase 5 (ERK5) in the aggressiveness of neuroblastoma, which is the most common solid type of tumor among children. According to Dr. Soriano, “the results of this project will be useful to obtain a biomarker of response to certain groups of patients that could response to the therapy based on the inhibition of the ERK5 kinase activity". The recent development of pharmacological inhibitors of ERK5 has positioned this kinase as a therapeutic target in many cancers among adults. However, it has never been analyzed in the case of child cancer. The prognosis of children with neuroblastoma is excellent in low risk patients, but worse in other stages. In fact, in the last 20 years, the survival of patients in the middle and high stages of the disease has not improved significantly and is among the 30 and 50%. For that reason, Dr. Soriano explains that “due to the existence of multiple mechanisms that cause the resistance to chemotherapy, and to the failure of current treatments, new therapeutic strategies are needed to treat the patients more effectively”. The project duration is 2 years, has been granted with 20,000 euros and will be developed in collaboration with the Protein Kinases and Signal Transduction in Neuronal Cells research group of the Universitat Autònoma de Barcelona (UAB). The AECC in Catalonia has granted a total of 5 Catalan research projects with 100,000 euros. </td></tr></table>comunica@vhir.org (VHIR)Mon, 9 Feb 2015 00:00:00 GMTDiscover the winners of the 4th VHIR' scientific images contest (06/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=20&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0020\2015_0020_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> We have the winners of the fourth edition of the VHIR’ scientific images contest! As it happened in last editions, it wasn’t easy for the jury to choose among the pictures presented, which stand out for their creative, original and analytic point of view, as well as for their shapes and colors. The best pictures are already decorating VHIR’s facilities and soon some of them will take part in an exhibition with the best of the four editions of the contest. We invite you to see all the pictures on our Facebook profile (click here). Once again we want to thank VHIR’s researchers for participating and sharing the pictures which represent the day-to-day of our biomedical research. See you on the next edition! </td></tr></table>comunica@vhir.org (VHIR)Fri, 6 Feb 2015 00:00:00 GMTHelp Dr. Cristina Sole to run the BCN Marathon for Lupus (04/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=19&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0019\2015_0019_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Cristina Solé, researcher of the Systemic Diseases group at Vall d’Hebron Institute of Research (VHIR), will run the 37th Edition of the&nbsp; Zurich Barcelona Marathon with a great challenge: to raise funds for research on Lupus disease. With this aim, she has created a challenge in migranodearena.org, that will be open until the day of the race, on March 15. The members of the research line in lupus at VHIR, led by Dr. José Ordi-Ros, together with the collaboration of the Catalan Lupus Foundation and the Albert Bosch Foundation, work heavily to conduct clinical trials, design and apply protocols for the treatments, and investigate the possible causes, new therapies and biomarkers to fight against the disease. The cause of Lupus is unknown, its evolution is uncertain and researchers have not found the cure yet. Each Lupus is different but, commonly, the antibodies use to attack the own organism instead of protect it against external agents. Patients with lupus feel very tired all day, suffer from the joints and many of them present skin injuries, or even severe injuries in many vital organs such as the kidney. With the challenge created in migranodearena and her effort, Dr. Solé aims to raise 2,000 euros. All funds collected will go directly to the research on these diseases that affect, only in Catalonia, more than 6,000 people. Collaborate </td></tr></table>comunica@vhir.org (VHIR)Wed, 4 Feb 2015 00:00:00 GMTMembers of the BERENICE consortium met at Vall d'Hebron for the 3rd General Assembly (02/02/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=18&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0018\2015_0018_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Members of BERENICE consortium about Chagas' disease, led by Dr. Israel Molina, researcher of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR), had their Third General Assembly on the 28th January 2015, in Barcelona. The main objective of the meeting was to discuss with its eight European and Latin American partners the progress of the project, which began on 1st September 2013, for a period of 5 years. BERENICE is funded under the European Community's 7th Framework Programme with the aim to obtain a more effective, better tolerated and cheaper formulation of a drug with trypanocidal activity to cure Chagas disease. During the meeting, the partners shared updates on project progress to date and discussed how to move forward both at Work Package and Consortium levels. The project is in a key moment to decide the final formulation to conduct clinical trials in humans. It is designed as an international multicenter clinical trial which will take place in the facilities of the Vall Hebron University Hospital and other sites such as Argentina, Bolivia or Mexico. The encapsulation of benznidazole using nanotechnology will generate a new drug delivery system. This new approach will allow a release of medication directly into the intracellular space, therefore increasing tissue drug concentration and avoiding side effects. A better toxic profile will be obtained because of the reduced amount of benznidazole used. </td></tr></table>comunica@vhir.org (VHIR)Mon, 2 Feb 2015 00:00:00 GMTResearchers identify a gene associated to higher survival from sepsis due to pneumonia (30/01/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=17&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0017\2015_0017_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the European Society of Intensive Care Medicine (ESICM) have identified a gene located in chromosome 5 that is associated to higher risk of survival from sepsis due to pneumonia or intra-abdominal infection contracted outside the hospital. Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia and Sepsis (CRIPS) group at Vall d’Hebron Institute of Research (VHIR), led the Spanish participation in this study published recently in The Lancet. The aim of the research was to determine whether the genetic factors contribute to the progress of the disease. With this purpose, researchers conducted the first genome-wide association study carried out in patients admitted to intensive care units with sepsis due to pneumonia. They analyzed up to 1.500 patients of whom the 23 per cent died within the intensive care unit admission. Among the results obtained, scientists identified this gene of the chromosome 5, called FER, that is carried by nearly the 20 per cent of the European population. The genetics of these people protects them from the progress of the disease and improves their response to the current treatments. Thanks to this discovery, Dr. Rello reports that they could “develop biomarkers for risk stratification, as well as potential novel targets for therapy or prevention of the complications”. Pneumonia is the main cause of severe sepsis, which is the inflammatory response of the body to the infections. Despite the latest advances on research, Dr. Rello assures that the mortality rate of sepsis due to pneumonia has never fallen from the 20 per cent. </td></tr></table>comunica@vhir.org (VHIR)Fri, 30 Jan 2015 00:00:00 GMT